KIRhub 2.0· v2

Ruxolitinib

134c3270-c3f1-550d-be21-4acdedd772e2 · FDA Approved · targets JAK1, JAK2, JAK3, TYK2

Ruxolitinib

MeasuredReference

Ruxolitinib targets JAK2, JAK3, TYK2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

JAK2 JAK3 TYK2 JAK1 CAMK2A

Top hallmarks

tumor promoting inflammation3.8k
evading apoptosis2.7k
proliferation2.6k

Top pathways disrupted

pi3k akt mtor signaling5.9k
apoptosis5.0k
allograft rejection4.6k

Resistance landscape — Ruxolitinib

MeasuredReference

1 known oncogenic variants exist on Ruxolitinib's top targets — see detail for inhibition impact.

JAK2 1 known variant
- JAK2 (V617F)

Open in new tab